Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China

Objective: To evaluate the cost-effectiveness of dabrafenib plus trametinib combination therapy versus vemurafenib as first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma from a healthcare system perspective in China. Methods: This study employed a pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Tianfu, Liu, Jia, Wu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226451/
https://www.ncbi.nlm.nih.gov/pubmed/34201096
http://dx.doi.org/10.3390/ijerph18126194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226451/
https://www.ncbi.nlm.nih.gov/pubmed/34201096
http://dx.doi.org/10.3390/ijerph18126194

Ejemplares similares